---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013487"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:15:30.744545+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q2 net loss widens to $29.6M; zunsemetinib RA data expected Q4 2023

## Summary
- Net loss $29.6M vs $20.5M YoY; revenue $1.9M vs $1.5M, driven by licensing royalties.
- Cash $210.8M, sufficient through 2025; includes $26.7M from ATM share sale in April 2023.
- Zunsemetinib Phase 2b RA trial enrollment completed; topline data expected Q4 2023.
- ATI-2138 Phase 1 MAD completed in healthy volunteers; data expected September 2023.
- G&A expenses $8.3M include bad debt from EPI Health bankruptcy filing.

## SEC filing metadata
- accession: 0001558370-23-013487
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023013487/0001558370-23-013487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023013487/acrs-20230807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013487
- JSON: https://secwatch.observer/filing/0001558370-23-013487.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.